Biodesix, Inc. (NASDAQ:BDSX) Receives $32.50 Consensus Price Target from Brokerages

Biodesix, Inc. (NASDAQ:BDSX) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $32.50.

Several research analysts have weighed in on the company. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd.

Institutional Trading of Biodesix

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in shares of Biodesix during the 3rd quarter worth $113,000. Oracle Investment Management Inc. acquired a new stake in shares of Biodesix in the 3rd quarter valued at $113,000. XTX Topco Ltd boosted its holdings in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares in the last quarter. Finally, Aberdeen Group plc acquired a new position in Biodesix during the fourth quarter worth $1,784,000. 20.96% of the stock is owned by institutional investors.

Biodesix Stock Down 5.4%

BDSX stock opened at $7.88 on Friday. The company has a 50 day moving average of $7.41 and a two-hundred day moving average of $7.51. The company has a market cap of $62.72 million, a price-to-earnings ratio of -1.42 and a beta of 0.60. Biodesix has a 12-month low of $3.44 and a 12-month high of $23.56. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million for the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. On average, equities analysts anticipate that Biodesix will post -0.35 earnings per share for the current fiscal year.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.